AR101363A1 - Derivado de cristal de azol benceno - Google Patents

Derivado de cristal de azol benceno

Info

Publication number
AR101363A1
AR101363A1 ARP150102422A ARP150102422A AR101363A1 AR 101363 A1 AR101363 A1 AR 101363A1 AR P150102422 A ARP150102422 A AR P150102422A AR P150102422 A ARP150102422 A AR P150102422A AR 101363 A1 AR101363 A1 AR 101363A1
Authority
AR
Argentina
Prior art keywords
benceno
azol
crystal
crystal derivative
derivative
Prior art date
Application number
ARP150102422A
Other languages
English (en)
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of AR101363A1 publication Critical patent/AR101363A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Reivindicación 1: Un cristal de ácido 2-[4-(2,2-dimetilpropoxi)-3-(1H-1,2,3,4-tetrazol-1-il)fenil]-4-metil-1,3-tiazol-5-carboxílico. Reivindicación 2: El cristal de acuerdo con la reivindicación 1, donde el cristal tiene la forma de cristal A.
ARP150102422A 2014-07-30 2015-07-29 Derivado de cristal de azol benceno AR101363A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014155031 2014-07-30

Publications (1)

Publication Number Publication Date
AR101363A1 true AR101363A1 (es) 2016-12-14

Family

ID=55217594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102422A AR101363A1 (es) 2014-07-30 2015-07-29 Derivado de cristal de azol benceno

Country Status (31)

Country Link
US (1) US9815826B2 (es)
EP (1) EP3176165B1 (es)
JP (1) JP6230713B2 (es)
KR (1) KR20170033321A (es)
CN (1) CN106536519B (es)
AR (1) AR101363A1 (es)
AU (1) AU2015297489B2 (es)
BR (1) BR112017001659A2 (es)
CA (1) CA2955485A1 (es)
CY (1) CY1120933T1 (es)
DK (1) DK3176165T3 (es)
ES (1) ES2693382T3 (es)
HR (1) HRP20181789T1 (es)
IL (1) IL250144B (es)
LT (1) LT3176165T (es)
MX (1) MX370375B (es)
MY (1) MY179339A (es)
NZ (1) NZ729045A (es)
PH (1) PH12017500123B1 (es)
PL (1) PL3176165T3 (es)
PT (1) PT3176165T (es)
RS (1) RS57797B1 (es)
RU (1) RU2675854C2 (es)
SA (1) SA517380786B1 (es)
SG (1) SG11201700742UA (es)
SI (1) SI3176165T1 (es)
SM (1) SMT201800646T1 (es)
TR (1) TR201818775T4 (es)
TW (1) TWI687418B (es)
WO (1) WO2016017696A1 (es)
ZA (1) ZA201700491B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955577A1 (en) * 2014-07-30 2016-02-04 Teijin Pharma Limited Xanthine oxidase inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092580T3 (es) 1990-11-30 1996-12-01 Teijin Ltd Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
DE69632854T2 (de) * 1995-04-07 2005-07-14 Teijin Ltd. Schutzmittel für Organe und Gewebe
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
AU2003290779A1 (en) * 2002-11-14 2004-06-03 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
JP5222561B2 (ja) * 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
WO2008126770A1 (ja) * 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
MX2009010491A (es) 2007-04-11 2009-11-09 Kissei Pharmaceutical Derivado heterociclico de 5 miembros y su uso para propositos medicos.
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
EP2536699A2 (en) * 2010-02-19 2012-12-26 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
EP2563768A4 (en) 2010-04-29 2013-07-31 Reddys Lab Ltd Dr MANUFACTURE OF FEBUXOSTAT
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物

Also Published As

Publication number Publication date
MX370375B (es) 2019-12-11
EP3176165A4 (en) 2017-06-07
IL250144B (en) 2019-11-28
HRP20181789T1 (hr) 2018-12-28
SI3176165T1 (sl) 2018-11-30
RU2017106058A3 (es) 2018-08-28
US9815826B2 (en) 2017-11-14
SA517380786B1 (ar) 2021-01-17
TW201619153A (zh) 2016-06-01
RS57797B1 (sr) 2018-12-31
DK3176165T3 (da) 2019-01-02
NZ729045A (en) 2022-05-27
US20170210735A1 (en) 2017-07-27
MX2017000513A (es) 2017-04-27
TR201818775T4 (tr) 2019-01-21
MY179339A (en) 2020-11-04
CA2955485A1 (en) 2016-02-04
SG11201700742UA (en) 2017-03-30
CN106536519A (zh) 2017-03-22
AU2015297489B2 (en) 2019-09-19
WO2016017696A1 (ja) 2016-02-04
ES2693382T3 (es) 2018-12-11
PH12017500123A1 (en) 2017-05-29
LT3176165T (lt) 2018-11-26
AU2015297489A1 (en) 2017-03-09
EP3176165B1 (en) 2018-09-26
EP3176165A1 (en) 2017-06-07
RU2675854C2 (ru) 2018-12-25
PT3176165T (pt) 2019-01-10
CY1120933T1 (el) 2019-12-11
ZA201700491B (en) 2018-04-25
BR112017001659A2 (pt) 2018-01-30
JP6230713B2 (ja) 2017-11-15
PL3176165T3 (pl) 2019-03-29
CN106536519B (zh) 2019-03-29
RU2017106058A (ru) 2018-08-28
PH12017500123B1 (en) 2021-01-20
IL250144A0 (en) 2017-03-30
KR20170033321A (ko) 2017-03-24
JPWO2016017696A1 (ja) 2017-04-27
TWI687418B (zh) 2020-03-11
SMT201800646T1 (it) 2019-01-11

Similar Documents

Publication Publication Date Title
LT3814347T (lt) Naftiridinono junginiai naudotini kaip t ląstelių aktyvatoriai
EA201691913A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
HUE049944T2 (hu) Karbamoiloximetil triazol ciklohexil savak LPA antagonistákként
EA201891211A1 (ru) Ингибиторы cxcr2
TWD179057S (zh) 充電器
CU20170057A7 (es) Derivados de feniltriazol sustituido con hidroxialquilo
CO2017000064A2 (es) Compuestos de [1,2,4]triazol sustituido
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
CL2015002309A1 (es) Proceso de fabricacion de vortioxetina.
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
CY1122506T1 (el) Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη
CL2015002358A1 (es) Compuestos bicíclicos.
MX2016015118A (es) Estimacion del volumen de sangre absoluto usando hemodilucion.
IT201800011142A1 (it) Forma per la produzione di calzature
AR101363A1 (es) Derivado de cristal de azol benceno
PH12017500124A1 (en) Azole benzene derivative and crystalline form thereof
UA93524U (uk) 5-(феноксиметил)-4-феніл-4н-1,2,4-триазол-3-тіол, що проявляє жарознижуючу активність
UA97068U (xx) 5-(феноксиметил)-4-етил-1,2,4-триазол-3-тіон, що виявляє гіпоглікемічну активність
UA108340U (uk) Морфолінію 1-н-бутилтеобромін-8-ілтіоацетат, який виявляє діуретичну дію
IT201700053882U1 (it) Mezzi per la produzione di calzature.
TH1601000345A (th) อนุพันธ์ 1-(พิเพอราซิน-1-อิล)-2-([1,2,4]ไตรอะโซล-1-อิล)-เอทาโนน
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
AR101362A1 (es) Derivado de azol benceno y forma cristalina del mismo
IT201600129161A1 (it) Dispositivo di alimentazione per macina-caffe'.

Legal Events

Date Code Title Description
FB Suspension of granting procedure